Comparative analysis of nootropic means of consumption in Ukraine, Estonia and Norway

Keywords: market analysis, consumption volumes, nootropic agents

Abstract

Cerebrovascular disease develops in neurodegenerative, vascular or cerebrovascular diseases of the brain. For their treatment, nootropic agents have neurotrophic, neuroprotective effects, increase brain energy exchange and cerebral circulation.

         The purpose of the study was to study the range and consumption of nootropic agents in the pharmaceutical market of Ukraine and to compare the volume and structure of their consumption with Estonia and Norway.

         The objects of this study were the representatives of two pharmacotherapeutic groups - NO6B «Psychostimulants and Nootropic Drugs» and N06D «Drugs used for dementia» present on the Ukrainian pharmaceutical market. The range of these drugs and the average retail price of their packs in the pharmacy network of Ukraine during the studied period were determined using the Morion Company Pharmexplorer market research system (as of December 2014, 2015, 2016, 2017). Drugs were performed according to DDDs/1 000 inhabitants/day or DID, using pharmacoepidemiological method of study ‒ ATC/DDD methodology.

         In the pharmaceutical market of Ukraine for 2014‒2017, nootropic drugs were represented from 204 tonnes (in 2014) to 237 tonnes (in 2017), based on 18 MNN, mainly domestic production. Drug prices varied over a wide range, which made it possible to choose a drug with nootropic action, taking into account the patient's financial capabilities. Vinpocetine (0.83‒0.98 DID) and piracetam (0.50‒0.52 DID) were predominantly consumed in the N06B group in Ukraine, while Ginkgo leaves (0.51‒0.59 DID) were the most consumed in the N06D group. and memantine (0.08‒0.18 DID). Consumption leaders are represented in the pharmaceutical market in a significant amount of TH and have a wide range of pricing for drug packaging. Compared to European countries, the consumption of nootropic drugs in Ukraine is almost 3.5 times lower than in Estonia and 2.4 times lower than in Norway. In terms of consumption in Ukraine and Estonia, the leaders were Ginkgo leaves, and in Norway, Donezepil.

         In the Ukrainian pharmaceutical market there is a sufficient assortment of products with nootropic action of mainly domestic production, which have a wide range of prices for the packaging of drugs. Consumption rates for drugs in Ukraine were low and inferior to two European countries, and in terms of consumption patterns similar to those of nootropic drugs in Estonia.

References

1. Pluzhnikova T. V., Kostrikov A. V. Analiz zakhvoriuvanosti na nevrolohichni khvoroby sered naselennia Poltavskoi oblasti za period 2007–2016 roky // Visn. VDNZU «Ukr. Med. stomatolohichna akad». – 2018. – T. 17, Vyp. 4 (60). – S. 206–208.
2. Ipatov A. V., Lysunets O. M., Khaniukova I. Ya. Pervynna invalidnist vnaslidok providnykh khvorob systemy krovoobihu v Ukraini (2015-2016 rr.) // Bukovynskyi med. visn. – 2017. – T. 21, № 2, Ch. 1. – S. 197–202.
3. Ivanova K. Nezdorov՚ia natsii // Novoe vremia. – 2018. – № 32. https://magazine.nv.ua/ukr/journal/3244-journal-no-32/nezdorovja-natsiji.html
4. Livingston G., Sommerlad A., Orgeta V. et al. Dementia prevention, intervention, and care // Lancet. – 2017. – V. 390. – P. 2673–2734.
5. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 // Lancet Neurol. – 2019. – V. 18. – P. 88–106. https://doi.org/10.1016/S1474-4422(18)30403-4
6. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) ta paliatyvnoi medychnoi dopomohy «Dementsiia». Nakaz MOZ Ukrainy № 736 vid 19. 07. 2016. https://dec.gov.ua/wp-content/uploads/images/dodatki/2016_736_Demencia/2016_736_YKPMD_Dem.pdf
7. Savelieva O. V., Shumova H. S., Vladymyrova I. M. Analiz farmatsevtychnoho rynku nootropnykh zasobiv v Ukraini // ScienceRise. – 2015. – № 11/4 (16). – S. 30–36.
8. Iakovlieva L. V., Rybka A. V. Tserebroprotektsiia v aspekti dokazovoi medytsyny: tserebrolizyn ta piratsetam // Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii. – 2013. – № 5. – S. 59–65. http://nbuv.gov.ua/UJRN/Uezyaf_2013_5_11
9. Slipchenko H. D., Piven O. P. Koniunkturnyi analiz asortymentu nootropnykh likarskykh zasobiv, zareiestrovanykh v Ukraini // Sotsialna farmatsiia v okhoroni zdorovia. – 2018. – T. 4, № 2. – C. 9-18.
10. Abdulkarim Al Nukari, Bushuieva I. V., Hladysheva S. A. Pozytsiiuvannia nootropnykh likarskykh zasobiv na natsionalnomu rynku // Akt. pytannia farmats. med. nauky ta praktyky. – 2018. – T. 11, № 3(28). – S. 339–345.
11. Mishchenko O. Ya., Khalieieva O. L., Berezniakov A. V. Analiz asortymentu ta ekonomichnoi dostupnosti nootropnykh preparativ v Ukraini / Farmakoekonomika v Ukraini: stan ta perspektyvy rozvytku. Mat. XI nauk.-prakt. Internet-konf., 24 travnia 2019 r., m. Kharkiv. – Kharkiv: NFaU, 2019. – S. 190–196.
12.Prohramnyi kompleks «Apteka» kompanii «Morion». https://pharmbase.com.ua/uk/optovi-propozitsiyi/
13. Morozov A. M., Yakovlieva L. V., Stepanenko A. V. ta in. Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy. Metod. rek. – Kharkiv: Styl-Izdat. – 2013. – 34 s.
14. Derzhavna sluzhba statystyky Ukrainy. www.ukrstat.gov.ua
15. Drug Consumption in Norway 2012‒2016. – Oslo: Folkehelseinstitutt, 2016. – 94 c. https://www.fhi.no/contentassets/0a8afbeb4c904d14b7b8a773bc25766e/legemiddelforbruket-2012-2016.pdf
16. Statistics on Medicines in Estonia 2013‒2016. ‒ Tartu: Green Print, 2017. 201 c. http://www.ravimiamet.ee/en/statistics-medicines
17. Gauthier S., Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials // Clin. Interv. Aging. – 2014. – V. 9. – P. 2065–2077.
18. Tan M. S., Yu J. T., Tan C. C. et al. Efficacy and adverse effects of ginkgo biloba forcognitive impairment and dementia: a systematic review and meta-analysis // J. Alzheimers Dis. – 2015. – V. 43, N 2. – P. 589–603.
19. Birks J. S., Harvey R. J. Donepezil for dementia due to Alzheimer’s disease // Cochrane Database Syst. Rev. – 2018. – June. 18, 6: CD001190.
20. Matsunaga S., Kishi T., Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis // PLoS One. – 2015. – V. 10 (4). ‒ P. 2015.
Published
2020-05-07
How to Cite
Tkachova, O. V., Iakovlieva, L. V., & Butko, Y. O. (2020). Comparative analysis of nootropic means of consumption in Ukraine, Estonia and Norway. Farmatsevtychnyi Zhurnal, (2), 26-38. https://doi.org/10.32352/0367-3057.2.20.03
Section
Management of pharmacy